Discontinued — last reported Q4 '20
An increase reflects continued investment or acquisition of long-term value drivers, while a decrease may result from impairment charges or the reclassification of assets.
This metric measures the book value of intangible assets related to a specific product that are not subject to amortizat...
Similar to other pharmaceutical companies, this represents the capitalized value of long-term intellectual property assets that are expected to provide sustained competitive advantages.
uthr_segment_trevyent_indefinite_lived_intangible_assets_excluding_goodwill